KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 123 filers reported holding KEROS THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.04 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $28,755,760 | -29.6% | 902,000 | -11.2% | 0.00% | 0.0% |
Q2 2023 | $40,818,983 | +1.2% | 1,015,903 | +7.6% | 0.00% | 0.0% |
Q1 2023 | $40,315,531 | -56.6% | 944,159 | -51.2% | 0.00% | -33.3% |
Q4 2022 | $92,979,974 | +164.8% | 1,936,276 | +107.4% | 0.00% | +50.0% |
Q3 2022 | $35,119,000 | +28.3% | 933,512 | -5.8% | 0.00% | 0.0% |
Q2 2022 | $27,374,000 | -26.4% | 990,752 | +44.9% | 0.00% | 0.0% |
Q1 2022 | $37,177,000 | -3.0% | 683,647 | +4.4% | 0.00% | 0.0% |
Q4 2021 | $38,324,000 | +43.0% | 654,992 | -3.3% | 0.00% | +100.0% |
Q3 2021 | $26,793,000 | -7.1% | 677,268 | -0.3% | 0.00% | -50.0% |
Q2 2021 | $28,836,000 | -35.3% | 678,978 | -6.2% | 0.00% | -33.3% |
Q1 2021 | $44,551,000 | +48.2% | 723,823 | +69.9% | 0.00% | +50.0% |
Q4 2020 | $30,056,000 | +685.4% | 426,091 | +329.4% | 0.00% | – |
Q3 2020 | $3,827,000 | +20.0% | 99,226 | +16.7% | 0.00% | – |
Q2 2020 | $3,189,000 | – | 85,011 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
Atom Investors LP | 49,981 | $3,526,000 | 0.36% |